| [1] |
Morris EJ, Maughan NJ, Forman D, et al. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology [J]. Gut, 2007, 56(10): 1419-1425.
|
| [2] |
Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients [J]. J Clin Oncol, 2015, 33(16): 1787-1796.
|
| [3] |
Benson AB, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J]. J Clin Oncol, 2004, 22(16): 3408-3419.
|
| [4] |
Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? [J]. J Clin Oncol, 2004, 22(10): 1797-1806.
|
| [5] |
Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study [J]. Lancet, 2007, 370(9604): 2020-2029.
|
| [6] |
Bockelman C, Engelmann BE, Kaprio T, et al. Risk of recurrence in patients with colon cancer stage II and III: a systematic review andmeta-analysis of recent literature [J]. Acta Oncol, 2015, 54(1): 5-16.
|
| [7] |
Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer [J]. N Engl J Med, 2005, 352(26): 2696-2704.
|
| [8] |
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J]. N Engl J Med, 2004, 350(23): 2343-2351.
|
| [9] |
Yothers G, O′Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses [J]. J Clin Oncol, 2011, 29(28): 3768-3774.
|
| [10] |
Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer [J]. J Clin Oncol, 2011, 29(11): 1465-1471.
|
| [11] |
司徒汪敏, 郑树.微卫星不稳定与Ⅱ期结直肠癌化疗的相关性探讨 [J]. 中华胃肠外科杂志, 2010, 13(12): 953-955.
|
| [12] |
Deligezer U, Yaman F, Erten N, et al. Frequent copresence of methylated DNA and fragmented nucleosomal DNA in plasma of lymphoma patients [J]. Clin Chim Acta, 2003, 335(12): 89-94.
|
| [13] |
张相国, 陈志仁. 微卫星不稳定与恶性肿瘤的研究进展 [J]. 中国医疗前沿, 2013, 18(13): 16-17.
|
| [14] |
Rui L, Tong S, Zhong LK, et al. Research progress of microsatellite instability′s judging prognosis and response to chemotherapy in colorectal cancer [J]. Chin J Clin Oncol, 2013, 40(4): 239-242.
|
| [15] |
Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer [J]. Cancer Res, 1998, 58(22): 5248-5257.
|
| [16] |
Buhard O, Cattaneo F, Wong YF, et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors [J]. J Clin Oncol, 2006, 24(2): 241-251.
|
| [17] |
Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer [J]. Expert Rev Gastroenterol Hepatol, 2011, 5(3): 385-399.
|
| [18] |
National Comprehensive Cancer Network: NCCN Guidelines: Colon Cancer, Version 2.2017.
URL
|
| [19] |
Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803 [J]. J Clin Oncol, 2009, 27(11): 1814-1821.
|
| [20] |
Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial [J]. J Clin Oncol, 2010, 28(3): 466-474.
|
| [21] |
Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer [J]. J Clin Oncol, 2011, 29(10): 1261-1270.
|
| [22] |
Klingbiel D, Saridaki Z, Roth AD, et al.Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial [J]. Ann Oncol, 2015, 26(1): 126-132.
|
| [23] |
Frank A, Sinicrope. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer [J]. Nat Rev Clin Oncol, 2010, 7(3): 174-177.
|
| [24] |
Kawakami H, Zaanan A, Sinicrope FA. Microsatellite instability testing and its role in the management of colorectal cancer [J]. Curr Treat Options Oncol, 2015, 16(7): 30.
|
| [25] |
Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer [J]. N Engl J Med, 2000, 342(2): 69-77.
|
| [26] |
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis [J]. J Clin Oncol, 2005, 23(3): 609-618.
|
| [27] |
Benatti P, Gafà R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis [J]. Clin Cancer Res, 2005, 11(23): 8332-8340.
|
| [28] |
Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy [J]. J Natl Cancer Inst, 2011, 103(11): 863-875.
|
| [29] |
Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer-- a study of CALGB 9581 and 89803 [J]. J Clin Oncol, 2011, 29(23): 3153-3162.
|
| [30] |
Merokl MA, Ahlquist TE, RФyrvik EC, et al. Microsatellite instability has a positive prognostic impact on stage . colorectal cancer after complete resection: results from a large, consecutive Norwegian series [J]. Annals of Oncology, 2013, 24(5): 1274-1282.
|
| [31] |
Sargent DJ, Shi Q, Yothers G, et al. Prognostic impact of deficient mismatch repair (dMMR) in 7, 803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database [J]. J Clin Oncol, 2014, 32(suppl; abstr 3507): 5s.
|
| [32] |
Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy [J]. J Clin Oncol, 2013, 31(29): 3664-3672.
|
| [33] |
Kim JE, Hong YS, Kim HJ, et al. Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy [J]. Ann Surg Oncol, 2015, 22(Suppl 3): S630-637.
|
| [34] |
Carethers JM, Chauhan DP, Fink D, et a1．Mismatch repair proficiency and in vitro response to 5-fluorouracil [J]. Gastroenterology, 1999, 117(1): 123-131．
|
| [35] |
Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines [J]. Int J Cancer, 2003, 106(1): 66-73.
|
| [36] |
Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer [J]. N Engl J Med, 2003, 349(3): 247-257.
|
| [37] |
R Jover, P Zapater, A Castells, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer [J]. Gut, 2006, 55(6): 848-855.
|
| [38] |
Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer [J]. J Clin Oncol, 2010, 28(20): 3219-3226.
|
| [39] |
Webber EM, Kauffman TL, O′Connor E, et al. Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy [J]. BMC Cancer, 2015, 15: 156.
|
| [40] |
Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J]. Ann Oncol, 2013, 24(suppl 6): vi64-72.
|